Oncology start-ups: Guardant Health and Flatiron Health partner against Cancer using Big Data and Analytics. The team will be generating a database of relevant genomic information, clinical trials and drug treatment results with the sole purpose of accelerating the development of new cancer drugs.
Flatiron Health Co-founder and Chief executive officer, Nat Turner believes that integrating clinical and genomic information has the potential to dramatically improve cancer treatment and advance therapy development. She further adds that Flatiron Health and Guardant Health's collective technology, oncology know-how and genomic expertise will be consequential in delivering an advanced, cloud-based platform to enhance patient care.
This collaboration will combine advanced clinical insights from the FlatironHealthOncologyCloud platform with genomic data sourced from Guardant Health's Guardant360® liquid biopsy platform. Guardant has developed a technology to read information with a blood test. As briefed about the work-frame, the blood stream consists of various traces of dead cells shredded from the progressing tumor. These dead cells are composed of a unique genetic tissue sensing from which Guardant can generate a complete genomic picture of the individual’s cancer progress, making it easier for disease targeting. Whereas, Flatiron being a cloud-based platform will aggregate data from all cancer treatment centers globally and is responsible for providing the structure and clinical trial information for the database.
"Today, oncologists and patients are demanding new therapies matched to their underlying tumor genomics to improve cancer treatment," said Guardant Health CEO and co-founder Helmy Eltoukhy. "Guardant360 removes the tissue barrier to accessing this genomic information in real-time. When combined with Flatiron Health's clinical data, this will significantly accelerate timelines for drug development, enabling many new treatment options for millions of cancer patients."
This HIPAA-compliant information platform is speculated to be available for life science companies by the first half of 2016.